icon-    folder.gif   Conference Reports for NATAP  
  (APASL) 23rd Conference of the Asian Pacific
Association for the Study of the Liver
6-9 June
2013, Singapore
Back grey_arrow_rt.gif
SVR Reduces HCC, decompensated cirrhosis, transplant, death by 50% & more: Projected Long-Term Impact of Vaniprevir (MK-7009) for Previously Treated Chronic HCV Genotype 1 Infection
  Reported by Jules Levin
APASL - Asian Pacific Association Liver Week
23rd Conference June 6 - 10, 2013, Singapore
from Jules: the importance from this study as I see it is the translation & quantification of SVR, any SVR from any combination therapy into reduced complications from liver-related disease: HCC, decompensated cirrhosis, transplant, death. In this case even though its an estimation from a model reductions in disease are high
Elamin H. Elbasha, Antoine C. El Khoury, Niloufar Mobashery Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA